Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inspire Pharmaceuticals has entered into an agreement with Boehringer Ingelheim to acquire certain exclusive rights to develop and market an intranasal dosage form of epinastine in the US and Canada for the treatment or prevention of rhinitis.
Subscribe to our email newsletter
Under this agreement, Inspire will have full responsibility for the drug’s development program and regulatory filings in the US and Canada, whilst Boehringer will be responsible for supplying Inspire with active drug substance. Meanwhile, Boehringer has retained the rights to develop and commercialize intranasal epinastine outside the US and Canada.
Inspire is paying Boehringer an upfront license fee, will fund all development activities and pay single digit royalties to Boehringer on net sales of the product, if approved, in the US and/or Canada. However, Inspire will not owe any additional milestone payments under the agreement.
Conversely, if Boehringer commercializes Inspire’s intranasal epinastine product outside of the US and Canada, it will pay royalties to Inspire on net sales of this product.
“The collaboration with Boehringer Ingelheim for the intranasal uses of epinastine represents an important expansion to Inspire’s development pipeline,” said Dr Christy Shaffer, president and CEO of Inspire. “This program will provide Inspire with the opportunity to build on our respiratory and allergy franchise, while leveraging our success in the market with the ocular form of epinastine, Elestat.”